Standard BioTools Inc. (LAB) income statement
LABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 12/3087% below fair value
$0.54−0.08 (-13.14%)
Close on Nov 17, 2026Market cap $211.76MP/E 2.5Yield –
Standard BioTools Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 50.5%
- Operating margin
- -112.8%
- Net margin
- 100.4%
- Return on equity, FY2025
- -16.7%
Financial strength
- Current ratio
- 9.10
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 475.4%
Valuation
- P/E ratio
- 2.5
- Price to sales
- 2.50
- Price to book
- 0.39
- Dividend yield
- –
See a number that looks wrong?